Supply of Study Drug Sample Clauses

Supply of Study Drug. Sponsor or its designee shall be responsible for providing, at no cost, to the Institution a sufficient supply of Study Drug. The Study Drug shall be shipped in due outer study-drug-packings and shall be identified in accordance with provisions of Article 19, paragraph 1(e) of Decree No. 226/2008 Coll., on Good Clinical Practice. The Institution´s Pharmacy shall be responsible for the Study Drug shipments receipt and for transfer of the Study Drug to the Principal Investigator and/or his/her authorised delegate. The Study Drug shall be delivered to Institution´s Pharmacy in business days and during regular business hours, i.e. 7AM – 3PM. 3.1
Sample 1
AutoNDA by SimpleDocs
Supply of Study Drug. Entropin will assure that the Study Drug is available on a timely basis and in amounts WCCS deems adequate to accommodate the patient treatment period as specified in the Protocol.
Sample 1
Supply of Study Drug. The Company shall provide the Fund, at its sole expense, with the Study Drug and Placebo (when applicable) required for the performance of the Study. The Fund shall maintain proper records concerning the administration of the Study Drug.
Sample 1
Supply of Study Drug. Sponsor or its designee shall be responsible for providing, at no cost, to the Institution a sufficient supply of Study Drug for the Study. The Study Drug shall be shipped in due outer study-drug-packings and shall be identified in accordance with provisions of 3.1
Sample 1

Related to Supply of Study Drug

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.